Pharma deal volume jumps 70% to €343.5bn Jan‑Jul 2026, led by Lilly, BMS, AbbVie and GSK
Executive summary: Pharmaceutical M&A and licensing volume rose 70% to €343.5 billion between January and July 2026, driven by deals involving Lilly, BMS, AbbVie and GSK. The surge signals accelerating consolidation in the pharma industry, which may affect drug pricing, competition and attract regulatory attention.
Who is involved: Eli Lilly, Bristol‑Myers Squibb (BMS), AbbVie, GSK and their advisors/investors.
Likely next: Continued deal flow through the rest of 2026, with potential antitrust reviews of the largest transactions.
The first seven months of 2026 saw pharmaceutical deal volume surge to €343.5 billion, a 70 % increase over the same period in 2025. Lilly, Bristol‑Myers Squibb, AbbVie and GSK were identified as the primary contributors to this uptick, reflecting a renewed wave of mergers, acquisitions and licensing agreements among the sector’s largest players. The surge is underpinned by several high‑value transactions already announced. GSK has agreed to acquire U.S.‑based cancer‑therapy company Nuvalent for approximately $10.6 billion, a move that would add a promising oncology pipeline to its portfolio. AbbVie has submitted a regulatory application to the European Medicines Agency for the subcutaneous induction formulation of SKYRIZI (risankizumab) in adults with moderate‑to‑severe Crohn’s disease, while its neuroscience franchise is projected by management to generate $12.7 billion in sales this year. These deals illustrate how big pharma is using M&A to fill therapeutic gaps and reinforce fast‑growing segments. If completed, the transactions are likely to shift competitive balances in oncology, immunology and neuroscience, potentially influencing pricing dynamics and market share over the next 12‑18 months.
Timeline
- — Lilly, BMS, AbbVie y GSK disparan las operaciones farmacéuticas (Expansión)
Analysis — what this means
Sectors affected
Historical parallels
- AbbVie’s Humira replacement strategy noted Aug 24 2026
- GSK eyed AnaptysBio acquisition Aug 17 2026
Key entities
Sources
Open the full interactive case file on Beyond →